

# **Epiomic Epidemiology Series: Uveitis Forecast in 18 Major Markets 2018–2028**

<https://marketpublishers.com/r/E090582AFA5EN.html>

Date: January 2018

Pages: 84

Price: US\$ 5,800.00 (Single User License)

ID: E090582AFA5EN

## **Abstracts**

### **Black Swan Analysis Epiomic Epidemiology Forecast Report on Uveitis in 18 Major Markets**

Uveitis is a general term denoting a group of inflammatory conditions of the eye. It affects mainly the uvea, a structure comprising the iris, ciliary body and choroid, but it can also affect nearby structures within the eye: the retina, vitreous humour and optic nerve. The condition constitutes a major cause of vision loss and blindness worldwide, but is thought to receive insufficient attention of healthcare professionals not specialised in ophthalmology. This report covers uveitis of immune and infectious origin, while excluding traumatic and post-operative uveitis, as well as Fuchs' heterochromic iridocyclitis.

This report provides the current prevalent population for uveitis across 18 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, uveitis categories based on location and aetiology, several features of uveitis patients, as well as the main comorbidities of the disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities of uveitis include:

Autoimmune diseases (systemic)

Ocular hypertension

Macular oedema

Epiretinal membrane

Diabetes mellitus

Tuberculosis and other infections

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

#### Reason to buy

Ability to quantify patient populations in global uveitis market to target the development of future products, pricing strategies and launch plans.

Further insight into the prevalence of the subdivided types of uveitis and identification of patient segments with high potential.

Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

Better understanding of the impact of specific co-morbid conditions on the prevalent population of uveitis patients.

Identification of uveitis patient sub-populations that require treatment.

Better understanding of the specific markets that have the largest number of uveitis patients.

## **Contents**

**INTRODUCTION**

**CAUSE OF THE DISEASE**

**RISK FACTORS & PREVENTION**

**DIAGNOSIS OF THE DISEASE**

**VARIATION BY GEOGRAPHY/ETHNICITY**

**DISEASE PROGNOSIS & CLINICAL COURSE**

**STANDARDISATION OF UVEITIS NOMENCLATURE (SUN) WORKING GROUP  
GUIDELINES**

**KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE**

**METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS**

**TOP-LINE PREVALENCE FOR UVEITIS**

**FEATURES OF UVEITIS PATIENTS**

**AETIOLOGY OF UVEITIS**

**INFECTIOUS CAUSES OF UVEITIS**

**AUTOIMMUNE CAUSES OF UVEITIS**

**VISION LOSS IN UVEITIS**

**COMORBID OPHTHALMIC CONDITIONS IN UVEITIS**

**ABBREVIATIONS USED IN THE REPORT**

**OTHER BLACK SWAN SERVICES & SOLUTIONS**

## **REPORTS & PUBLICATIONS**

## **ONLINE EPIDEMIOLOGY DATABASES**

## **ONLINE PHARMACEUTICAL PRICING DATABASE**

## **REFERENCES**

## **APPENDIX**

## List Of Tables

### LIST OF TABLES AND FIGURES

Table 1. Signs and symptoms of uveitis by the affected section of the eye
Table 2. The SUN working group descriptors of uveitis
Table 3. Prevalence of uveitis, total (000s)
Table 4. Prevalence of uveitis, males (000s)
Table 5. Prevalence of uveitis, females (000s)
Table 6. Patients with uveitis by anatomical site, total (000s)
Table 7. Patients with anterior uveitis by aetiology, total (000s)
Table 8. Patients with anterior uveitis by duration of attack, total (000s)
Table 9. Patients with intermediate uveitis by aetiology, total (000s)
Table 10. Patients with posterior uveitis by aetiology, total (000s)
Table 11. Patients with panuveitis by aetiology, total (000s)
Table 12. Patients with infectious uveitis by causal agent, total (000s)
Table 13. Patients with autoimmune uveitis by causal condition, total (000s)
Table 14. Uveitis patients with vision loss (acuity $\geq 6/18$ ), total (000s)
Table 15. Uveitis patients with vision loss (acuity $\geq 6/18$ ) by laterality, total (000s)
Table 16. Uveitis patients with vision loss (acuity $\geq 6/18$ ) by cause, total (000s)
Table 17. Uveitis patients with hypopyon, total (000s)
Table 18. Uveitis patients with ocular hypertension, total (000s)
Table 19. Uveitis patients with macular oedema, total (000s)
Table 20. Uveitis patients with epiretinal membranes, total (000s)
Table 21. Abbreviations and acronyms used in the report
Table 22. USA prevalence of uveitis by 5-yr age cohort, males (000s)
Table 23. USA prevalence of uveitis by 5-yr age cohort, females (000s)
Table 24. Canada prevalence of uveitis by 5-yr age cohort, males (000s)
Table 25. Canada prevalence of uveitis by 5-yr age cohort, females (000s)
Table 26. France prevalence of uveitis by 5-yr age cohort, males (000s)
Table 27. France prevalence of uveitis by 5-yr age cohort, females (000s)
Table 28. Germany prevalence of uveitis by 5-yr age cohort, males (000s)
Table 29. Germany prevalence of uveitis by 5-yr age cohort, females (000s)
Table 30. Italy prevalence of uveitis by 5-yr age cohort, males (000s)
Table 31. Italy prevalence of uveitis by 5-yr age cohort, females (000s)
Table 32. Spain prevalence of uveitis by 5-yr age cohort, males (000s)
Table 33. Spain prevalence of uveitis by 5-yr age cohort, females (000s)
Table 34. UK prevalence of uveitis by 5-yr age cohort, males (000s)
Table 35. UK prevalence of uveitis by 5-yr age cohort, females (000s)

Table 36. Poland prevalence of uveitis by 5-yr age cohort, males (000s)  
Table 37. Poland prevalence of uveitis by 5-yr age cohort, females (000s)  
Table 38. Netherlands prevalence of uveitis by 5-yr age cohort, males (000s)  
Table 39. Netherlands prevalence of uveitis by 5-yr age cohort, females (000s)  
Table 40. Turkey prevalence of uveitis by 5-yr age cohort, males (000s)  
Table 41. Turkey prevalence of uveitis by 5-yr age cohort, females (000s)  
Table 42. Japan prevalence of uveitis by 5-yr age cohort, males (000s)  
Table 43. Japan prevalence of uveitis by 5-yr age cohort, females (000s)  
Table 44. China prevalence of uveitis by 5-yr age cohort, males (000s)  
Table 45. China prevalence of uveitis by 5-yr age cohort, females (000s)  
Table 46. South Korea prevalence of uveitis by 5-yr age cohort, males (000s)  
Table 47. South Korea prevalence of uveitis by 5-yr age cohort, females (000s)  
Table 48. India prevalence of uveitis by 5-yr age cohort, males (000s)  
Table 49. India prevalence of uveitis by 5-yr age cohort, females (000s)  
Table 50. Australia prevalence of uveitis by 5-yr age cohort, males (000s)  
Table 51. Australia prevalence of uveitis by 5-yr age cohort, females (000s)  
Table 52. Brazil prevalence of uveitis by 5-yr age cohort, males (000s)  
Table 53. Brazil prevalence of uveitis by 5-yr age cohort, females (000s)  
Table 54. Mexico prevalence of uveitis by 5-yr age cohort, males (000s)  
Table 55. Mexico prevalence of uveitis by 5-yr age cohort, females (000s)  
Table 56. Argentina prevalence of uveitis by 5-yr age cohort, males (000s)  
Table 57. Argentina prevalence of uveitis by 5-yr age cohort, females (000s)  
Figure 1. Colour representation of the eye sections affected by each anatomical category of uveitis: blue—anterior uveitis, green—intermediate uveitis, purple—posterior uveitis; panuveitis encompasses all three sections

## I would like to order

Product name: Epiomic Epidemiology Series: Uveitis Forecast in 18 Major Markets 2018–2028

Product link: <https://marketpublishers.com/r/E090582AFA5EN.html>

Price: US\$ 5,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E090582AFA5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970